C3 and paroxysmal nocturnal hemoglobinuria: So far, Empaveli (pegcetacoplan injection) (13) and Syfovre (pegcetacoplan intraocular injection) (6) have been successfully launched for the treatment of PNH and GA, respectively, both of which used an anti-C3 cyclic peptide from the compstatin family as the active motif.